Orgenesis Inc. Share Price

Equities

ORGS

US68619K2042

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 02:00:01 27/04/2024 am IST 5-day change 1st Jan Change
0.5071 USD +0.62% Intraday chart for Orgenesis Inc. +1.24% +1.28%
Sales 2022 36.02M 3B Sales 2023 530K 44.19M Capitalization 15.96M 1.33B
Net income 2022 -14M -1.17B Net income 2023 -55M -4.59B EV / Sales 2022 1.8 x
Net Debt 2022 14.96M 1.25B Net Debt 2023 21.78M 1.82B EV / Sales 2023 71.2 x
P/E ratio 2022
-3.29 x
P/E ratio 2023
-0.26 x
Employees 146
Yield 2022 *
-
Yield 2023
-
Free-Float 78.99%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.62%
1 week+1.24%
Current month-38.31%
1 month-38.31%
3 months+63.32%
6 months-44.79%
Current year+1.28%
More quotes
1 week
0.49
Extreme 0.4925
0.52
1 month
0.30
Extreme 0.3044
0.88
Current year
0.25
Extreme 0.25
0.91
1 year
0.25
Extreme 0.25
1.50
3 years
0.25
Extreme 0.25
6.47
5 years
0.25
Extreme 0.25
8.30
10 years
0.25
Extreme 0.25
16.80
More quotes
Managers TitleAgeSince
Founder 70 05/08/05
Chief Executive Officer 55 02/12/02
Director of Finance/CFO 54 02/01
Members of the board TitleAgeSince
Director/Board Member 64 18/13/18
Chief Executive Officer 55 02/12/02
Director/Board Member 54 09/20/09
More insiders
Date Price Change Volume
26/24/26 0.5071 +0.62% 24,517
25/24/25 0.504 +0.40% 11,934
24/24/24 0.502 -3.28% 35,608
23/24/23 0.519 +2.33% 18,415
22/24/22 0.5072 +1.26% 22,024

Delayed Quote Nasdaq, April 27, 2024 at 02:00 am IST

More quotes
Orgenesis Inc. is a biotech company focused on cell and gene therapies (CGTs). The Company focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. It operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Company’s therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomera’s services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.
More about the company